Zentalis Pharmaceuticals Inc (ZNTL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.99-2.92%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ZNTL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -69.5% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ZNTL — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026, and commented on certain business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated herein by reference.
Why it matters: Conference presentations will show how well azenosertib works. They will also show its market potential. This can change how investors feel.
Watch forGood clinical data will be shared at big conferences like ASCO or ESMO.
Also watch forBad clinical data will be shared at big conferences or no new data will be shown.
Why it matters: Better dosing could lead to better trial results. It may help with future approvals.
Supportive ifResults showing effective dosing come out from the DENALI trial.
Worry ifResults show that the current dosing is ineffective or needs adjustment.
Why it matters: If the healthcare sector's revenue growth speeds up, it could help Zentalis. It may signal a better market for their drugs.
Supportive ifHealthcare sector revenue growth returns to above 10% year over year.
Worry ifHealthcare sector revenue growth remains below 10% year over year.
Why it matters: Finishing enrollment in DENALI Part 2c is key for the study's success. It is also important for the regulatory plan.
Supportive ifDENALI Part 2c enrollment finishes on time. This allows for quick data analysis.
Worry ifEnrollment in DENALI Part 2c is delayed or falls short of expected numbers.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$238 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $1,028 loss on $10,000 · 10.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,675 loss on $10,000 · 46.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Cash updates will show if the company can pay for trials and operations.
Worry ifCash position stays stable or grows. This shows strong financial health.
Less concerning ifCash position drops a lot. This raises worries about funding future trials.
Why it matters: This readout will show if azenosertib can get faster approval for ovarian cancer. Good results could increase trust in the drug.
Supportive ifTopline readout shows good results for DENALI Part 2. This suggests azenosertib may get faster approval.
Worry ifThe main results are not good. This raises concerns about how well azenosertib works.
Why it matters: Enrollment progress will show how well Zentalis is working to get full approval for azenosertib. High enrollment helps the drug's market chances.
Supportive ifEnrollment reaches or goes beyond 420 patients in the ASPENOVA trial. This shows strong interest and support.
Worry ifEnrollment stops or does not meet targets. This suggests possible problems with the trial's appeal.